Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of huntington's disease

Neuropsychopharmacology

Volumn 36, Issue 12, 2011, Pages 2406-2421

  Chiu, Chi Tso ^a   Liu, Guangping ^a   Leeds, Peter ^a   Chuang, De Maw ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

GSK 3; HDACs; Huntingtons disease; lithium; transgenic mouse model; valproate

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 70; HISTONE DEACETYLASE 3; LITHIUM CARBONATE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COORDINATION; CORPUS STRIATUM; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; ENZYME INHIBITION; FEMALE; FORCED SWIMMING TEST; GENETIC ASSOCIATION; HISTONE ACETYLATION; HUNTINGTON CHOREA; LEARNING; LOCOMOTION; MALE; MAZE TEST; MONOTHERAPY; MOTOR PERFORMANCE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ROTAROD TEST; SURVIVAL TIME; TAIL SUSPENSION TEST; TRANSGENIC MOUSE;

AFFECT; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUNTINGTON DISEASE; LITHIUM; MALE; MICE; MICE, TRANSGENIC; VALPROIC ACID;

EID: 80054772539     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.128     Document Type: Article

References (94)

1. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC et al (2008). Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 105: 1333-1338. (Pubitemid 351397053)
2. Bemelmans AP, Horellou P, Pradier L, Brunet I, Colin P, Mallet J (1999). Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther 10: 2987-2997.
3. Bersudsky Y, Shaldubina A, Belmaker RH (2007). Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss. Behav Pharmacol 18: 77-80. (Pubitemid 46103286)
4. Beurel E, Michalek SM, Jope RS (2010). Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 31: 24-31.
5. Buitrago MM, Schulz JB, Dichgans J, Luft AR (2004). Short and long-term motor skill learning in an accelerated rotarod training paradigm. Neurobiol Learn Mem 81: 211-216. (Pubitemid 38479661)
6. Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martin-Ibanez R, Munoz MT et al (2004). Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci 24: 7727-7739. (Pubitemid 39186828)
7. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC (2002). Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 277: 33791-33798.
8. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP et al (1999). Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19: 3248-3257. (Pubitemid 29174016)
9. Chalecka-Franaszek E, Chuang DM (1999). Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 96: 8745-8750. (Pubitemid 29354862)
10. Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM (2000). Mechanisms of chaperone suppression of polyglutamine disease: Selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet 9: 2811-2820.
11. Chen G, Huang LD, Jiang YM, Manji HK (1999). The moodstabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72: 1327-1330. (Pubitemid 29085050)
12. Chiang MC, Chen HM, Lee YH, Chang HH, Wu YC, Soong BW et al (2007). Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease. Hum Mol Genet 16: 483-498.
13. Chiu CT, Chuang DM (2010). Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 128: 281-304.
14. Chuang DM (2005). The antiapoptotic actions of mood stabilizers: Molecular mechanisms and therapeutic potentials. Ann NY Acad Sci 1053: 195-204.
15. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT (2009). Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32: 591-601.
16. Crawley JN (1985). Exploratory behavior models of anxiety in mice. Neurosci Biobehav Rev 9: 37-44. (Pubitemid 15136669)
17. Cryan JF, Mombereau C (2004). In search of a depressed mouse: Utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 9: 326-357. (Pubitemid 38534696)
18. Cryan JF, Mombereau C, Vassout A (2005). The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29: 571-625. (Pubitemid 40755457)
19. de Angelis L (1992). The anxiogenic-like effects of pentylenetetrazole in mice treated chronically with carbamazepine or valproate. Methods Find Exp Clin Pharmacol 14: 767-771. (Pubitemid 23076463)
20. De Sarno P, Li X, Jope RS (2002). Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43: 1158-1164. (Pubitemid 36009369)
21. Di ML, Squitieri F, Napolitano G, Campanella G, Trofatter JA, Conneally PM (1993). Suicide risk in Huntington's disease. J Med Genet 30: 293-295. (Pubitemid 23120483)
22. Duan W, Guo Z, Jiang H, Ware M, Li XJ, Mattson MP (2003). Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA 100: 2911-2916. (Pubitemid 36297597)
23. Duan W, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B et al (2008). Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol Dis 30: 312-322.
24. Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM (2008). Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 155: 567-572.
25. Ferrer I, Goutan E, Marin C, Rey MJ, Ribalta T (2000). Brainderived neurotrophic factor in Huntington disease. Brain Res 866: 257-261. (Pubitemid 30313028)
26. File SE, Mahal A, Mangiarini L, Bates GP (1998). Striking changes in anxiety in Huntington's disease transgenic mice. Brain Res 805: 234-240. (Pubitemid 29005139)
27. Fink AL (1999). Chaperone-mediated protein folding. Physiol Rev 79: 425-449. (Pubitemid 29210927)
28. Friedlander RM (2003). Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348: 1365-1375. (Pubitemid 36384105)
29. Fujimoto M, Takaki E, Hayashi T, Kitaura Y, Tanaka Y, Inouye S et al (2005). Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J Biol Chem 280: 34908-34916. (Pubitemid 41504625)
30. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S (2001). Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 158: 100-106.
31. Göttlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978. (Pubitemid 34062289)
32. Gould TD, Chen G, Manji HK (2004). In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29: 32-38. (Pubitemid 38068011)
33. Gould TD, O'Donnell KC, Dow ER, Du J, Chen G, Manji HK (2008). Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology 54: 577-587.
34. Grimes CA, Jope RS (2001). The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65: 391-426. (Pubitemid 32781670)
35. Gusella JF, MacDonald ME (1995). Huntington's disease. Semin Cell Biol 6: 21-28.
36. Hamilton JM, Salmon DP, Corey-Bloom J, Gamst A, Paulsen JS, Jerkins S et al (2003). Behavioural abnormalities contribute to functional decline in Huntington's disease. J Neurol Neurosurg Psychiatry 74: 120-122. (Pubitemid 36069050)
37. Hartl FU, Hayer-Hartl M (2002). Molecular chaperones in the cytosol: From nascent chain to folded protein. Science 295: 1852-1858. (Pubitemid 34214115)
38. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM (2002). Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: An essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43: 1173-1179. (Pubitemid 36009371)
39. Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R et al (2004). Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 13: 1389-1405. (Pubitemid 38961645)
40. Hickey MA, Chesselet MF (2003). Apoptosis in Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 27: 255-265. (Pubitemid 36351493)
41. Hickey MA, Kosmalska A, Enayati J, Cohen R, Zeitlin S, Levine MS et al (2008). Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 157: 280-295.
42. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G et al (2006). Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15: 965-977. (Pubitemid 43338237)
43. Huang HC, Klein PS (2006). Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease. Curr Drug Targets 7: 1389-1397. (Pubitemid 44718299)
44. Jana NR, Tanaka M,Wang G, Nukina N (2000). Polyglutamine lengthdependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity. Hum Mol Genet 9: 2009-2018. (Pubitemid 30642666)
45. Jones BJ, Roberts DJ (1968). A rotarod suitable for quantitative measurements of motor incoordination in naive mice. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 259: 211.
46. Jope RS, Yuskaitis CJ, Beurel E (2007). Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics. Neurochem Res 32: 577-595. (Pubitemid 46481289)
47. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar- Finkelman H (2004). Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 55: 781-784. (Pubitemid 38429867)
48. Kells AP, Fong DM, Dragunow M, During MJ, Young D, Connor B (2004). AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 9: 682-688. (Pubitemid 38660421)
49. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM (2007). Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: Multiple mechanisms of action. J Pharmacol Exp Ther 321: 892-901. (Pubitemid 46762687)
50. Klein PS, Melton DA (1996). A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93: 8455-8459. (Pubitemid 26269579)
51. Klivenyi P, Bende Z, Hartai Z, Penke Z, Nemeth H, Toldi J et al (2006). Behaviour changes in a transgenic model of Huntington's disease. Behav Brain Res 169: 137-141. (Pubitemid 43277479)
52. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM (2008). Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: Roles of glycogen synthase kinase-3 inhibition. J Neurosci 28: 2576-2588. (Pubitemid 351348211)
53. Liaw YW, Liu YW, Chen BK, Chang WC (1998). Induction of 12-lipoxygenase expression by phorbol 12-myristate 13-acetate in human epidermoid carcinoma A431 cells. Biochim Biophys Acta 1389: 23-33.
54. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L et al (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983. (Pubitemid 23110238)
55. Marinova Z, Ren M, Wendland JR, Leng Y, Liang MH, Yasuda S et al (2009). Valproic acid induces functional heat-shock protein 70 via class I histone deacetylase inhibition in cortical neurons: A potential role of Sp1 acetylation. J Neurochem 111: 976-987.
56. Martin JB, Gusella JF (1986). Huntington's disease. Pathogenesis and management. N Engl J Med 315: 1267-1276.
57. Menalled L, El-Khodor BF, Patry M, Suarez-Farinas M, Orenstein SJ, Zahasky B et al (2009). Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis 35: 319-336.
58. Morales LM, Estevez J, Suarez H, Villalobos R, Chacin de BL, Bonilla E (1989). Nutritional evaluation of Huntington disease patients. Am J Clin Nutr 50: 145-150. (Pubitemid 19195534)
59. Nakao N, Brundin P, Funa K, Lindvall O, Odin P (1995). Trophic and protective actions of brain-derived neurotrophic factor on striatal DARPP-32-containing neurons in vitro. Brain Res Dev Brain Res 90: 92-101.
60. O'Brien WT, Harper AD, Jove F, Woodgett JR, Maretto S, Piccolo S et al (2004). Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 24: 6791-6798. (Pubitemid 38993901)
61. Omata N, Chiu CT, Moya PR, Leng Y, Wang Z, Hunsberger JG et al (2011). Lentivirally mediated GSK-3beta silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. Int J Neuropsychopharmacol 14: 711-717.
62. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
63. Porsolt RD, Bertin A, Jalfre M (1977). Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327-336. (Pubitemid 8225714)
64. Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersen A et al (2009). Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 132: 919-932.
65. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM (2004). Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: Potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 89: 1358-1367. (Pubitemid 38802657)
66. Ren M, Senatorov VV, Chen RW, Chuang DM (2003). Postinsult treatment with lithium reduces brain damage and facilitatesneurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci USA 100: 6210-6215. (Pubitemid 36576955)
67. Rosa AO, Kaster MP, Binfare RW, Morales S, Martin-Aparicio E, Navarro-Rico ML et al (2008). Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatry 32: 1549-1556.
68. Rowe MK, Chuang DM (2004). Lithium neuroprotection: Molecular mechanisms and clinical implications. Expert Rev Mol Med 6: 1-18.
69. Rowe MK, Wiest C, Chuang DM (2007). GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 31: 920-931. (Pubitemid 47285347)
70. Rubinsztein DC (2002). Lessons from animal models of Huntington's disease. Trends Genet 18: 202-209. (Pubitemid 34273741)
71. Ryves WJ, Harwood AJ (2001). Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280: 720-725. (Pubitemid 32924489)
72. Sangdee C, Franz DN (1978). Lithium-induced enhancement of 5-HT transmission at a central synapse. Commun Psychopharmacol 2: 191-198.
73. Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55-66.
74. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA et al (1999). Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8: 397-407. (Pubitemid 29097327)
75. Schroeder FA, Lin CL, Crusio WE, Akbarian S (2007). Antidepressant- like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 62: 55-64. (Pubitemid 46898220)
76. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT (1994). Behavioural and pharmacological characterisation of the elevated ''zero-maze'' as an animal model of anxiety. Psychopharmacology (Berl) 116: 56-64. (Pubitemid 24279597)
77. Slow EJ, van RJ, Rogers D, Coleman SH, Graham RK, Deng Y et al (2003). Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12: 1555-1567. (Pubitemid 36857303)
78. Stack EC, Ferrante RJ (2007). Huntington's disease: Progress and potential in the field. Expert Opin Investig Drugs 16: 1933-1953. (Pubitemid 351403725)
79. Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology (Berl) 85: 367-370. (Pubitemid 15123115)
80. Sugars KL, Rubinsztein DC (2003). Transcriptional abnormalities in Huntington disease. Trends Genet 19: 233-238. (Pubitemid 36511427)
81. Tekin S, Cummings JL (2002). Frontal-subcortical neuronal circuits and clinical neuropsychiatry: An update. J Psychosom Res 53: 647-654. (Pubitemid 36292444)
82. Treiser SL, Cascio CS, O'Donohue TL, Thoa NB, Jacobowitz DM, Kellar KJ (1981). Lithium increases serotonin release and decreases serotonin receptors in the hippocampus. Science 213: 1529-1531. (Pubitemid 11031243)
83. Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Velasquez L (2004). Assessment of the nutrition status of patients with Huntington's disease. Nutrition 20: 192-196. (Pubitemid 38220981)
84. Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J et al (2007). Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis 26: 189-200. (Pubitemid 46436497)
85. Ventimiglia R, Mather PE, Jones BE, Lindsay RM (1995). The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur J Neurosci 7: 213-222.
86. Vonsattel JP, DiFiglia M (1998). Huntington disease. J Neuropathol Exp Neurol 57: 369-384. (Pubitemid 28237321)
87. Wheelock VL, Tempkin T, Marder K, Nance M, Myers RH, Zhao H et al (2003). Predictors of nursing home placement in Huntington disease. Neurology 60: 998-1001. (Pubitemid 36348935)
88. Woo NH, Lu B (2006). Regulation of cortical interneurons by neurotrophins: From development to cognitive disorders. Neuroscientist 12: 43-56. (Pubitemid 43122382)
89. Wood NI, Morton AJ (2003). Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res Bull 61: 375-383. (Pubitemid 36945468)
90. Yamanaka T, Miyazaki H, Oyama F, Kurosawa M, Washizu C, Doi H et al (2008). Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. EMBO J 27: 827-839. (Pubitemid 351417169)
91. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM (2009). The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14: 51-59.
92. Zadori D, Geisz A, Vamos E, Vecsei L, Klivenyi P (2009). Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol Biochem Behav 94: 148-153.
93. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS (2003). Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278: 33067-33077. (Pubitemid 37055753)
94. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L et al (2001). Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293: 493-498. (Pubitemid 32679077)